EPO a Human, His
Sf9, Baculovirus cells.
Greater than 95% as determined by SDS-PAGE.
Description
EPO a Human Recombinant produced in Baculovirus is a single, glycosylated polypeptide chain containing 174 amino acids (28-193a.a.) and having a molecular mass of 19.5kDa.
EPO a is fused to an 8 amino acid His-tag at C-terminus & purified by proprietary chromatographic techniques.
Product Specs
Sf9, Baculovirus cells.
APPRLICDSR VLERYLLEAK EAENITTGCA EHCSLNENIT VPDTKVNFYA WKRMEVGQQA VEVWQGLALL SEAVLRGQAL LVNSSQPWEP LQLHVDKAVS GLRSLTTLLR ALRAQKEAIS PPDAASAAPL RTITADTFRK LFRVYSNFLR GKLKLYTGEA CRTGDRLEHH HHHH.
Product Science Overview
EPO-α is composed of four alpha-helical bundles and is glycosylated, which is crucial for its stability and biological activity. The recombinant form of EPO-α, produced in Baculovirus cells, consists of a single, glycosylated polypeptide chain containing 174 amino acids (28-193a.a.) and has a molecular mass of approximately 19.5 kDa . This recombinant protein is fused to an 8 amino acid His-tag at the C-terminus, which facilitates its purification through chromatographic techniques .
EPO-α plays a critical role in erythropoiesis, the process of red blood cell production. It promotes erythroid differentiation and initiates hemoglobin synthesis, thereby increasing the oxygen-carrying capacity of the blood . Beyond its hematopoietic functions, EPO-α also exhibits neuroprotective activity against various brain injuries and has anti-apoptotic functions in several tissue types .
The recombinant form of EPO-α is produced using Baculovirus expression systems in Sf9 cells. The His-tagged version allows for efficient purification using nickel affinity chromatography, ensuring a high degree of purity (>95%) as determined by SDS-PAGE . The protein solution is typically formulated in phosphate-buffered saline (PBS) with 10% glycerol to maintain stability .
Recombinant EPO-α is widely used in research and clinical settings. It is employed in cell proliferation assays, particularly using TF-1 human erythroleukemic cells, to measure its biological activity. The ED50 (effective dose for 50% of the population) for EPO-α is ≤0.5 ng/ml . Clinically, EPO-α is used to treat anemia, especially in patients with chronic kidney disease, malignancies, and those undergoing chemotherapy .
For short-term storage (2-4 weeks), EPO-α should be kept at 4°C. For longer periods, it is recommended to store the protein at -20°C with the addition of a carrier protein (0.1% HSA or BSA) to prevent degradation. It is crucial to avoid multiple freeze-thaw cycles to maintain the protein’s integrity .
